News and Trends 15 Dec 2016 Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […] December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 Liquid Biopsies: Lowering the Defenses of Resistant Lung Cancer In response to new treatments, cancer came back stronger and more resistant than ever. Medicine’s counterattack will be more effective with a clear target. How do you solve a problem like drug resistance in cancer research? There’s no clear-cut answer yet, not least because the disease can vary so widely. But there has been some […] December 14, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 Swedish Therapy targeting All Solid Tumors enrolls First Patient Immunicum just received FDA approval to start clinical trials in the US for a therapy that could overcome the challenges of T-cell therapies and target virtually any injectable solid tumor. Immunicum is a biotech from Gothenburg, Sweden, that focuses on immuno-oncology with a different approach from most companies. Instead of T-cells, the company engineers dendritic […] December 14, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 What do the CAR-T Patient Deaths Mean for the Future of the Field? Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno Therapeutics again came under scrutiny last month following deaths in its JCAR015 trial. Two patients died from neurotoxicity-triggered cerebral edema, the same condition that killed […] December 14, 2016 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Lifting the Chemo Fog: Virtual Reality has Medical Applications! Cancer can make life unbearable for some patients, but sometimes the treatment only adds to the pain. Could virtual reality treatments improve their lives? The vast majority of modern cancer therapies are focused on halting the progression and the spread of the disease to save the patient’s life. These treatments are usually aggressive, and approximately […] December 9, 2016 - 3 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 The Munich Biotech Mafia expand to the US with a New TCR Startup TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […] December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 Sanofi Jumps into the Biosimilars Market aiming for Asia Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […] December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 How is European Immuno-Oncology fighting Blood Cancer? From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […] December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2016 Another Pharma sloughs off Small Molecules to focus on Biologics BI has taken an axe to its small molecule discovery program in order to focus on immuno-oncology in the latest farewell to old-school chemical drugs. Over 90% of the drugs on the market today are small molecules, but the bell has been tolling for these therapies for some time now as biopharma is increasingly focused […] December 5, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2016 Video: Chatting with Immunocore about the Potential of Immuno-oncology At Refresh in Paris, I had the opportunity to ask Eva-Lotta Allan,CBO of one of Europe’s hottest companies, Immunocore, some pointed questions. Immunocore is famous as one of the biggest biotech successes in Europe: the company raised the largest round ever on the continent (€300M!), built a solid technological platform and recruited top talents to manage […] December 5, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […] December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email